Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 458

1.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9942-9. [Epub ahead of print]

PMID:
30155789
2.

Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures.

Kraemer M, Karakaya R, Matsushige T, Graf J, Albrecht P, Hartung HP, Berlit P, Laumer R, Diesner F.

J Neurol. 2018 Aug 28. doi: 10.1007/s00415-018-9031-4. [Epub ahead of print]

PMID:
30155735
3.

Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy.

Graf J, Jansen L, Ingwersen J, Ringelstein M, Harmel J, Rybak J, Kolbe R, Rhöse L, Gemerzki L, Lee JI, Klistorner A, Guthoff R, Hartung HP, Aktas O, Albrecht P.

Ann Clin Transl Neurol. 2018 Jul 7;5(8):952-961. doi: 10.1002/acn3.593. eCollection 2018 Aug.

4.

Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA-bypass surgery in Europe-a retrospective analysis of 64 procedures.

Kraemer M, Sassen J, Karakaya R, Schwitalla JC, Graf J, Albrecht P, Hartung HP, Diehl RR, Berlit P, Laumer R, Diesner F.

J Neurol. 2018 Aug 17. doi: 10.1007/s00415-018-8997-2. [Epub ahead of print]

PMID:
30120561
5.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
6.

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.

Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP.

Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9.

PMID:
30001923
7.

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

Leussink VI, Montalban X, Hartung HP.

CNS Drugs. 2018 Jul 10. doi: 10.1007/s40263-018-0536-2. [Epub ahead of print] Review.

PMID:
29992409
8.

150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.

Lehmann HC, Compston A, Hartung HP.

Neurology. 2018 May 29;90(22):1011-1016. doi: 10.1212/WNL.0000000000005613.

PMID:
29807916
9.

Intravenous versus subcutaneous immunoglobulin - Authors' reply.

van Schaik IN, Mielke O; PATH study group.

Lancet Neurol. 2018 May;17(5):393-394. doi: 10.1016/S1474-4422(18)30109-1. No abstract available.

PMID:
29656738
10.

ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.

Kremer D, Küry P, Hartung HP.

Mult Scler. 2018 May;24(6):696-700. doi: 10.1177/1352458518768770. Epub 2018 Apr 9.

PMID:
29629605
11.

A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.

J Peripher Nerv Syst. 2018 Jun;23(2):108-114. doi: 10.1111/jns.12267. Epub 2018 Apr 26.

12.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

13.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

14.

Human Endogenous Retroviruses in Neurological Diseases.

Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, Giovannoni G, Hartung HP, Perron H.

Trends Mol Med. 2018 Apr;24(4):379-394. doi: 10.1016/j.molmed.2018.02.007. Epub 2018 Mar 15. Review.

15.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
16.

Teriflunomide promotes oligodendroglial differentiation and myelination.

Göttle P, Manousi A, Kremer D, Reiche L, Hartung HP, Küry P.

J Neuroinflammation. 2018 Mar 13;15(1):76. doi: 10.1186/s12974-018-1110-z.

17.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2018 Mar 1:1352458518763089. doi: 10.1177/1352458518763089. [Epub ahead of print]

PMID:
29521573
18.

Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model.

Dietrich M, Helling N, Hilla A, Heskamp A, Issberner A, Hildebrandt T, Kohne Z, Küry P, Berndt C, Aktas O, Fischer D, Hartung HP, Albrecht P.

J Neuroinflammation. 2018 Mar 7;15(1):71. doi: 10.1186/s12974-018-1111-y.

19.

Progress in Recognizing and Treating Polyneuropathy.

Kieseier BC, Hartung HP.

Dtsch Arztebl Int. 2018 Feb 9;115(6):81-82. doi: 10.3238/arztebl.2018.0081. No abstract available.

20.

Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis.

Ingwersen J, De Santi L, Wingerath B, Graf J, Koop B, Schneider R, Hecker C, Schröter F, Bayer M, Engelke AD, Dietrich M, Albrecht P, Hartung HP, Annunziata P, Aktas O, Prozorovski T.

J Neurochem. 2018 Feb 23. doi: 10.1111/jnc.14324. [Epub ahead of print]

PMID:
29473171

Supplemental Content

Loading ...
Support Center